Literature DB >> 8131123

Canadian study of health and aging: study methods and prevalence of dementia.

.   

Abstract

OBJECTIVE: To estimate the prevalence of dementia and its subtypes by sex and age group for five regions of Canada.
DESIGN: Prevalence survey.
SETTING: Community and institutional settings in Canada, excluding those in the two territories, Indian reserves and military units. PARTICIPANTS: Representative sample of people aged 65 and over interviewed between February 1991 and May 1992. Those in the community (9008 subjects) were chosen randomly from medicare lists in nine provinces or from the Enumeration Composite Record in Ontario. People in institutions (1255) were randomly selected from residents in stratified random samples of institutions in each region.
INTERVENTIONS: Screening with the Modified Mini-Mental State (3MS) Examination to identify cognitive impairment. Clinical examination of all those in institutions, those in the community with a 3MS score of less than 78 and a sample of those in the community with a 3MS score of 78 or more to diagnose dementia. Dementia and Alzheimer's disease were defined according to established criteria. MAIN OUTCOME MEASURES: Prevalence of dementia of all types, by region, sex and age group, the estimated number of cases in the population by type of dementia and the age-standardized rate per 1000 population.
RESULTS: The prevalence estimates suggested that 252,600 (8.0%) of all Canadians aged 65 and over met the criteria for dementia (95% confidence interval [CI] 236,800 to 268,400). These were divided roughly equally between the community and institutional samples; the female:male ratio was 2:1. The age-standardized rate ranged from 2.4%, among those aged 65 to 74 years, to 34.5%, among those aged 85 and over. The corresponding figures for Alzheimer's disease were 5.1% overall (161,000 cases; 95% CI 148,100 to 173,900), ranging from 1.0% to 26.0%; for vascular dementia it was 1.5% overall, ranging from 0.6% to 4.8%. If the prevalence estimates remain constant, the number of Canadians with dementia will rise to 592,000 by 2021.
CONCLUSIONS: These Canadian estimates of the prevalence of dementia fall toward the upper end of the ranges in other studies, whereas the estimates for Alzheimer's disease fall in the middle of the ranges. This may suggest an unusual balance between Alzheimer's and other forms of dementia in the Canadian population.

Entities:  

Mesh:

Year:  1994        PMID: 8131123      PMCID: PMC1486712     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  25 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity.

Authors:  R P Ryseck; C Raynoschek; H Macdonald-Bravo; K Dorfman; M G Mattéi; R Bravo
Journal:  Cell Growth Differ       Date:  1992-07

3.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

4.  Some calculations on the prevalence of dementia in Canada.

Authors:  E R Jeans; E Helmes; H Merskey; J M Robertson; K A Rand
Journal:  Can J Psychiatry       Date:  1987-03       Impact factor: 4.356

Review 5.  The prevalence of dementia: a quantitative integration of the literature.

Authors:  A F Jorm; A E Korten; A S Henderson
Journal:  Acta Psychiatr Scand       Date:  1987-11       Impact factor: 6.392

6.  Dementia in Melton Mowbray--a validation of earlier findings.

Authors:  C Jagger; M Clarke; J Anderson; T Battcock
Journal:  Age Ageing       Date:  1992-05       Impact factor: 10.668

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Prevalence of dementia in a Japanese elderly population.

Authors:  H Shibayama; Y Kasahara; H Kobayashi
Journal:  Acta Psychiatr Scand       Date:  1986-08       Impact factor: 6.392

9.  Cognitive impairment in the elderly--a community survey.

Authors:  M Clarke; R Lowry; S Clarke
Journal:  Age Ageing       Date:  1986-09       Impact factor: 10.668

10.  Is the prevalence of dementia changing?

Authors:  C M Beard; E Kokmen; K Offord; L T Kurland
Journal:  Neurology       Date:  1991-12       Impact factor: 9.910

View more
  181 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Weight change, nutritional risk and its determinants among cognitively intact and demented elderly Canadians.

Authors:  B Shatenstein; M J Kergoat; S Nadon
Journal:  Can J Public Health       Date:  2001 Mar-Apr

4.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 5.  Health status assessment of the elderly.

Authors:  I Turpie; D Strang; P Darzins; G Guyatt
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

6.  Combination hormone replacement therapy and dementia.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

7.  Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects.

Authors:  Nikolaos Scarmeas; Eric Zarahn; Karen E Anderson; John Hilton; Joseph Flynn; Ronald L Van Heertum; Harold A Sackeim; Yaakov Stern
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

8.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Relationship between persistent pain and 5-year mortality: a population-based prospective cohort study.

Authors:  Joseph W Shega; Melissa Andrew; Ashwin Kotwal; Denys T Lau; Keela Herr; Mary Ersek; Debra K Weiner; Marshall H Chin; William Dale
Journal:  J Am Geriatr Soc       Date:  2013-12-09       Impact factor: 5.562

Review 10.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.